FDA clears Artemis' image-guided breast biopsy device:
This article was originally published in Clinica
Executive Summary
Artemis Medical has received US FDA 510(k) clearance for its MiniTome breast biopsy system. The device can localise and immobilise target breast tissue more precisely than current techniques, Artemis claims. It can also accurately cut and remove a large, architecturally intact sample through a minimally invasive incision. An intact sample provides a more definitive diagnosis, explains the Hayward, California firm. Around 1.4 million breast biopsies are performed in the US annually, over 50% of which use open surgical techniques in order to acquire a large intact sample, notes the company.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.